Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

08-252025

Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab

Guangzhou, China/Bad Vilbel, Germany –Bio-Thera will maintainresponsibility for development, manufacturing, and supply o...
07-162025

Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi®

Guangzhou – July 16, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing...
07-022025

IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial

Guangzhou,China – July 2025 – Bio-Thera Solutions, Inc. (688177:SH), a commercial-stagebiopharmaceutical company develop...

上一页 ···3 4 5 6 7 ··· 下一页